| abstract |
The present invention describes 1-butyl-2-hydroxyaralkyl piperazine derivatives and their use as antidepressants. The derivatives of the present invention have a triple inhibitory effect on the resorption of 5-HT, NA and DA, and can be administered to patients in need thereof in the form of compositions by the route of oral administration, injection and the like. Compared with the dual target antidepressants currently used clinically (eg venlafaxine), these derivatives may have stronger antidepressant effects, broader indications, faster onset and lower neurotoxicity and side reactions; The derivatives also have stronger antidepressant activity, lower toxicity, higher bioavailability, longer half-life and better drug performance compared to the arylalkanol piperazine derivatives and optical isomers thereof described in the prior art. The 1-butyl-2-hydroxy aralkyl piperazine derivative is a free alkali or salt thereof of a compound of the formula: |